Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...

Chronic kidney disease (CKD) affects more than 700 million people worldwide and is caused by genetic and environmental factors, as well as existing medical conditions. Known genetic risk factors for ...

Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...